A case-control study of rheumatoid arthritis identifies an associated single nucleotide polymorphism in the NCF4 gene, supporting a role for the NADPH-oxidase complex in autoimmunity by Olsson, Lina M et al.
Open Access
Available online http://arthritis-research.com/content/9/5/R98
Page 1 of 11
(page number not for citation purposes)
Vol 9 No 5 Research article
A case-control study of rheumatoid arthritis identifies an 
associated single nucleotide polymorphism in the NCF4 gene, 
supporting a role for the NADPH-oxidase complex in 
autoimmunity
Lina M Olsson1, Anna-Karin Lindqvist1,2, Henrik Källberg3, Leonid Padyukov4, Harald Burkhardt5, 
Lars Alfredsson3, Lars Klareskog4 and Rikard Holmdahl1
1Medical Inflammation Research, Lund University, BMC I11, 221 84, Lund, Sweden
2Cartela AB, Box 709, SE-220 07 Lund Sweden
3Institute for Environmental Medicine, Karolinska Institutet, Box 210, 171 77, Stockholm, Sweden
4Rheumatology Unit, Department of Medicine, Karolinska Institutet, 171 76, Stockholm, Sweden
5Division of rheumatology, Johann Wolfgang Goethe University, Theodor-Stern-Kai, 60596 Frankfurt am Main, Germany
Corresponding author: Lina M Olsson, lina.olsson@med.lu.se
Received: 22 Jul 2007 Revisions requested: 30 Aug 2007 Revisions received: 17 Sep 2007 Accepted: 26 Sep 2007 Published: 26 Sep 2007
Arthritis Research & Therapy 2007, 9:R98 (doi:10.1186/ar2299)
This article is online at: http://arthritis-research.com/content/9/5/R98
© 2007 Olsson et al.; licensee BioMed Central Ltd. 
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Rheumatoid arthritis (RA) is a chronic inflammatory disease with
a heritability of 60%. Genetic contributions to RA are made by
multiple genes, but only a few gene associations have yet been
confirmed. By studying animal models, reduced capacity of the
NADPH-oxidase (NOX) complex, caused by a single nucleotide
polymorphism (SNP) in one of its components (the NCF1 gene),
has been found to increase severity of arthritis. To our
knowledge, however, no studies investigating the potential role
played by reduced reactive oxygen species production in human
RA have yet been reported. In order to examine the role played
by the NOX complex in RA, we investigated the association of
51 SNPs in five genes of the NOX complex (CYBB, CYBA,
NCF4, NCF2, and RAC2) in a Swedish case-control cohort
consisting of 1,842 RA cases and 1,038 control individuals.
Several SNPs were found to be mildly associated in men in
NCF4 (rs729749, P = 0.001), NCF2 (rs789181, P = 0.02) and
RAC2 (rs1476002, P = 0.05). No associations were detected
in CYBA or CYBB. By stratifying for autoantibody status, we
identified a strong association for rs729749 (in NCF4) in
autoantibody negative disease, with the strongest association
detected in rheumatoid factor negative men (CT genotype
versus CC genotype: odds ratio 0.34, 95% confidence interval
0.2 to 0.6; P = 0.0001). To our knowledge, this is the first
genetic association identified between RA and the NOX
complex, and it supports previous findings from animal models
of the importance of reactive oxygen species production
capacity to the development of arthritis.
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disease
that leads to erosion and deformation of the joints. The preva-
lence in the general population is 0.5% to 1%, and women are
at two to three times greater risk for developing the disease.
Twin studies show a concordance rate of 12% to 15% in
monozygotic twins and 4% in dizygotic twins, and the genetic
heritability is estimated at 60% [1]. Despite much effort to
identify arthritis causing genes, only few genetic loci have
been confirmed to be associated with RA, among which are
the human leucocyte antigen (HLA) locus and the protein tyro-
sine phosphatase non-receptor 22 gene (PTPN22) [2-4].
RA is a heterogeneous disease with symptoms and disease
progression that vary between patients. Classification of typi-
cal RA requires fulfilment of four out of seven criteria estab-
lished by the American College of Rheumatology [5]. The
heterogeneity of the symptoms in RA probably mirrors the
CCP = cyclic citrullinated peptide; CEPH = Centre d'Etude du Polymorphisme Humain; CI = confidence interval; EIRA = Epidemiological Investiga-
tion of Rheumatoid Arthritis; HWE = Hardy-Weinberg equilibrium; NOX = NADPH oxidase; OR = odds ratio; RA = rheumatoid arthritis; RF = rheu-
matoid factor; ROS = reactive oxygen species; SE = shared epitope; SNP = single nucleotide polymorphism.Arthritis Research & Therapy    Vol 9 No 5    Olsson et al.
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underlying genetic contribution; hence, the various combina-
tions of symptoms observed in patients are probably caused
by different combinations of risk alleles.
In the search for markers that can predict development of the
disease before its onset, several autoantibodies, including
rheumatoid factors (RFs) and antibodies against cyclic citrulli-
nated peptides (anti-CCP antibodies), have been detected [6-
8]. RFs, autoantibodies that recognize the Fc part of immu-
noglobulins [9], are present in 60% to 70% of RA patients and
have been found to be associated with more severe clinical
manifestations [10,11]. Anti-CCP antibodies are present in
50% to 60% of RA patients and have also been shown to pre-
dict more severe disease [10,12-14]. Interestingly, recent data
suggest that the HLA-DRB1 locus, which has been shown to
be associated with RA, is only associated with the presence of
anti-CCP antibodies, and this association is independent of
both RA development and the presence of RFs [15]. Together
with recent data describing the interaction between environ-
mental factors and genetic predisposition [16,17], these find-
ings support the hypothesis that several independent disease
mechanisms may lead to development of RA. They also
emphasize the need to use relevant subgroups of RA patients
in genetic association studies.
Various approaches have been used to identify genes that
contribute to common diseases such as RA [18,19]. Because
of increasing knowledge of gene functions and immunological
pathways, a candidate gene approach can be more efficient in
terms of both cost and time than traditional linkage analysis or
genome-wide approaches. The selection of genes in a candi-
date gene study can be based on previous knowledge of gene
functions as well as on disease or immunological mechanisms.
It can also be based on findings in animal models.
The Pia4 locus in rats has been shown to reduce the severity
of pristane-induced arthritis (an arthritis model) [20]. A single
nucleotide polymorphism (SNP) in the Ncf1 gene was found
to be responsible for the protective effect [21]. Ncf1 encodes
the protein p47phox, which is part of the NADPH-oxidase
(NOX) complex that produces reactive oxygen species (ROS)
in response to infectious stimuli. Rats carrying the risk allele
have reduced capacity to produce ROS, which is linked to
increased risk for development of arthritis [21,22]. Apart from
NCF1, the NOX complex is composed of five other proteins
encoded by the genes NCF2,  NCF4,  CYBB,  CYBA  and
RAC2  [23,24]. In phagocytes massive ROS production,
called the oxidative burst, takes place in the phagosome or
endosome (intracellular) or in the plasma membrane (extracel-
lular) after ingestion of invading pathogens or after stimulation
of innate immune receptors [25-27]. However, the ability to
generate ROS extends to cells other than classical phago-
cytes, such as dendritic cells, suggesting that the NOX com-
plex has additional functions in the immune system [28].
Interestingly, recent findings from our group show that the
redox balance of T-cell membranes has an important effect on
the activation and proliferation of T cells [29].
Results obtain in animal models make NCF1 and the other
genes of the NOX complex candidate genes for human RA.
However, transferring animal data to the human setting is not
straightforward in this case. In contrast to rats, the genomic
organization of NCF1 in humans is very complex, which makes
SNP-based association analysis difficult [30,31]. However,
because of the complex interplay between the proteins of the
NOX complex, it is likely that genetic changes in any of the
genes could have the same effect on ROS production, as is
seen for Ncf1 in rats.
We used a candidate gene approach to study the association
with RA of 51 SNPs in five genes included in the NOX com-
plex. We found a SNP, located in intron 4 in NCF4, to be asso-
ciated with RA in a Swedish case-control cohort. This
supports the hypotheses that the NOX complex is involved in
the development of RA and that ROS could be an important
regulator of the immune system.
Materials and methods
Selection of single nucleotide polymorphism
The HapMap genome browser [32] was used as the primary
source for selection of SNPs. Primarily, HapMap-validated
SNPs were selected. However, in order to obtain evenly dis-
persed SNPs across the genes, SNPs were also selected
from dbSNP [33]. The selection was based on several criteria;
the minor allele frequency should be more than 5% in the Cen-
tre d'Etude du Polymorphisme Humain (CEPH) or other Euro-
pean cohort, the SNP should be located in a nonrepetitive
sequence, and the validation status at dbSNP should be at
least two-hit. We also consulted the Linkage disequilibrium
(LD) maps of the HapMap CEPH samples in order to disperse
evenly the SNPs with respect to the LD structure. Sixty-seven
SNPs were selected (see Additional file 1): six in CYBB, eight
in CYBA, 22 in NCF2, 21 in NCF4 and 10 in RAC2. The
number of SNPs selected in each gene reflects both the size
of the gene and the availability of validated SNPs.
Samples
Samples from the Epidemiological Investigation of Rheuma-
toid Arthritis (EIRA), a population based case-control study,
were analyzed. The study base comprised the population,
aged 18 to 70 years, in a geographically defined area in the
middle and southern parts of Sweden during the period from
May 1996 to 2005. A case was defined as a person in the
study base who, during the study period and for the first time,
received a diagnosis of RA based on the American College of
Rheumatology criteria of 1987 [5]. All cases were examined
and diagnosed by a rheumatologist at a participating centre.
All public rheumatology units in the study area and almost all
of the (very few) private units participated in the study. The
present study includes data from 1,842 RA patients andAvailable online http://arthritis-research.com/content/9/5/R98
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1,038 controls, randomly selected from the study base and
matched on age, sex and residential area. Of the cases and
controls, 71% and 72%, respectively, are female; the mean
age was 51 ± 13 years in cases and 54 ± 12 in controls. Infor-
mation about RF and anti-CCP antibody status was available
for 1,315 of the patient samples; 63% of these were RF posi-
tive and 61% were anti-CCP positive.
Genotyping
Assay design, validation and genotyping were performed by
Kbiosciences (London, UK) using a fluorescence resonance
energy transfer based competitive allele-specific polymerase
chain reaction system (KASPar).
Of the selected 67 SNPs, 51 were successfully turned into
assays. Six SNPs failed to make good assays (rs1049255
[CYBA], rs699244, rs789180, rs4652813 and rs6667363
[NCF2], and rs2075938 [NCF4]), whereas 10 were mono-
morphic in the panel of 40 Caucasians used for validation or
in the EIRA cohort (rs1804006 [CYBA], rs789183,
rs13306581 and rs13306575 [NCF2], and rs13057803,
rs1003501, rs12158689, rs9610595, rs2072706 and
rs2072711 [NCF4]; Additional file 1). Fourteen of the SNPs
were genotyped in all available samples (1,842 cases and
1,038 controls), whereas the other 37 SNPs were genotyped
in a subset of the samples comprising 1,069 patients and 634
controls (Additional file 1).
Hardy-Weinberg analysis
The Haploview software calculates P  values for deviations
from Hardy-Weinberg equilibrium (HWE) for each marker on
the complete uploaded dataset [34]. A significance threshold
of P ≤ 0.001 was used. In order to obtain HWE P values for
the case and control groups separately, each dataset was
uploaded separately.
Single marker analysis
Contingency tables were created for each SNP using the JMP
5.0 software (SAS Institute, Cary, NC, USA), and P values for
association with RA were calculated using χ2 tests for geno-
type frequencies. The sample set was stratified for sex in the
initial analysis, and for sex and RF or anti-CCP status in the
stratified analysis. Because CYBB is located on the X chromo-
some, allele frequencies were used to estimate association in
the male samples.
To obtain a corrected α level in the stratified analysis, the Bon-
ferroni correction method was applied, as implemented on the
simple interactive statistical analysis website [35].
We also performed logistic regression analysis for the
rs729749 SNP, in order to adjust for age, sex and living area.
Logistic regression analysis was conducted for a subset of the
material, in which all information regarding genetic factors,
antibodies and matching variables was available. This same
sample set was used for the frequency analysis of rs729749.
We used the SAS software for Windows (version 9.1; SAS
Institute, Cary, NC, USA) to perform logistic regression
analysis.
Haplotype analysis
Haplotype blocks were calculated using Haploview [34].
SNPs that departed from HWE in both cases and controls
were excluded from the analysis. The haplotype predictions
were based on the CI method proposed by Gabriel and cow-
orkers [36]. However, the other available methods yielded the
same result. Haplotypes were assessed using the WHAP soft-
ware [37]. Sub-haplotypes were investigated for associations
based on the block structure predicted in Haploview. Because
the haplotype block analysis is based on all genotyped SNPs,
we used only the genotype information from the subset of the
EIRA cohort comprising 1,069 cases and 634 controls. The
permuted P values for the haplotypes are based on 5,000
permutations.
Genome analysis
The region surrounding rs729749 was investigated for the
presence of regulatory elements, transcription factor binding
sites and conserved regions using the University of California,
Santa Cruz (UCSC) Genome Browser [38]. The ESPERR
Regulatory potential (seven species), Conservation, and TFBS
Conservation options were used.
P values and odds ratios (OR) with 95% CIs for the genetic
models were calculated using the GraphPad Prism software
(GraphPad Software, San Diego, CA, USA).
Results
Fifty-one single nucleotide polymorphisms were 
successfully genotyped in a Swedish rheumatoid 
arthritis cohort
To investigate the genes in the NOX complex for association
with RA, 67 SNPs evenly dispersed in the five candidate
genes (Table 1) were selected from the HapMap genome
browser and dbSNP (National Center for Biotechnology Infor-
mation; Additional file 1). Fifty-one out of the 67 SNPs were
successfully assayed and genotyped in the Swedish EIRA
cohort [39,40], with a 98% call rate (Additional file 1). Devia-
tions from HWE were estimated for each SNP in all samples
combined and in cases and controls separately. The SNP
rs3788524 (NCF4) significantly deviated from HWE (P  <
0.001) in both the case and control groups, indicating a pos-
sible genotype failure.
Genotype analysis indicates male-specific associations 
with rheumatoid arthritis in NCF2, NCF4 and RAC2
To evaluate the SNPs for association with RA, contingency
tables were created for genotype frequencies and P values
were calculated using χ2 tests. Because RA is more frequent
in women than in men, the disease mechanisms might be sexArthritis Research & Therapy    Vol 9 No 5    Olsson et al.
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dependent. The samples were therefore analyzed either all
together or stratified by sex. The initial cut-off P value for sig-
nificance was set at 0.05 to reduce the risk for missing sub-
group-specific associations, which would be weak in the
complete sample set. Three SNPs fulfilled this criterion for
association with RA, all in men; rs789181 in NCF2 (P = 0.03),
rs729749 in NCF4 (P = 0.001) and rs1476002 in RAC2 (P
= 0.05; Table 2).
Stratification based on autoantibody status reveals a 
highly significant association of rs729749 with 
rheumatoid factor negative rheumatoid arthritis in men
Because RA is a heterogeneous disease, it is likely that the
disease contributing genes differ in different subgroups of
patients. Presence or absence of autoantibodies such as RF
and anti-CCP antibodies might reflect different underlying dis-
ease mechanisms. In order to determine whether the detected
associations are specific for a subclass of RA, we stratified the
male cases by RF or anti-CCP antibody status and performed
an analysis on genotype frequencies for the associated SNPs.
We found the SNPs rs789181 (NCF2) and rs1476002
(RAC2) to be significantly associated in RF-positive men (P =
0.03 and 0.02, respectively). The SNP rs1476002 was also
significantly associated in anti-CCP antibody positive men (P
= 0.05). However, the P values are only slightly improved com-
pared with the initial analysis, suggesting that the associations
are not specific for any of these subgroups. On the other hand,
the association for rs729749 in NCF4 is highly significant in
RF-negative men (P = 0.0002), whereas no association was
detected in RF-positive men (P = 0.0713; Table 3). Further-
more, a comparison of the frequencies in RF-negative against
RF-positive men also yielded a significant association with RF-
negative disease (P = 0.01). We also detected a weaker asso-
ciation in anti-CCP antibody negative men (P = 0.003; Table
3), although the anti-CCP antibody negative versus anti-CCP
antibody positive comparison is not significant (P  = 0.08).
Logistic regression analysis of the CT or TT genotype against
the CC genotype, adjusted for age and residential area, also
indicated a sex and subgroup specific effect for rs729749
(Table 4). With regard to RF-negative RA among men, the OR
for CT against CC is 0.34 (95% CI = 0.20 to 0.60; P  =
0.0001). Here we also see a strong association in anti-CCP
antibody negative men (OR = 0.4, 95% CI = 0.2 to 0.7; P =
0.0004).
To determine the validity of the P value, we estimated a cor-
rected α value using the Bonferroni correction method. The
corrected α level for the number of tests performed (159) was
estimated at 0.0003. Hence, only the association detected for




Gene Chromosome Position Exons (n)
NCF2 1 181,791,321 to 181,826,339 15
NCF4 22 35,586,991 to 35,604,004 10
CYBB X 37,524,264 to 37,557,658 13
CYBA 16 87,237,199 to 87,244,958 6
RAC2 22 35,951,258 to 35,970,251 7
Positions according to National Center for Biotechnology Information build 36.1 from the University of California, Santa Cruz genome browser.
Table 2
Associated SNPs in the initial genotype analysis
SNP id Case/control Genotype Sex P
rs729749 Case CC 0.69 (256) CT 0.26 (95) TT 0.05 (18) Male 0.001
Control CC 0.57 (141) CT 0.40 (98) TT 0.04 (9)
rs789181 Case AA 0.81 (244) AG 0.15 (46) GG 0.03 (10) Male 0.03
Control AA 0.78 (146) AG 0.22 (41) GG 0.005 (1)
rs1476002 Case CC 0.77 (395) CT 0.22 (115) TT 0.01 (6) Male 0.05
Control CC 0.76 (229) CT 0.20 (61) TT 0.04 (11)
SNP, single nucleotide polymorphism. Values indicate the genotype frequencies and number (in brackets).Available online http://arthritis-research.com/content/9/5/R98
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Haplotype analysis reveals an associated haplotype in 
NCF4 caused by the rs729749 single nucleotide 
polymorphism
We wished to estimate haplotypes and haplotype blocks to
determine whether rs729749 is included in a conserved and
possibly associated haplotype. The Haploview software was
used to determine the haplotype block structures of the genes.
The analysis showed that the NCF4 gene is divided into three
blocks (Figure 1). One block of 1 kilobase contains rs729749
as well as three other genotyped SNPs: rs760519,
rs2284027 and rs17811059. To test the association of the
haplotype blocks, we used the WHAP software. The block
containing rs729749 is borderline significant in the nonstrati-
fied analysis (P  = 0.055), but excluding rs2284027 and
rs17811059 yields a significant association (empirical P =
0.04 in all and 0.03 in men; Table 5). In order to determine how
Table 3
Stratified analysis of rs729749 in men
Antibody status Case/control Genotypes P
CC CT TT
RF positive Case 0.68 (169) 0.29 (71) 0.03 (7) 0.0713
Control 0.58 (170) 0.37 (108) 0.04 (11)
RF negative Case 0.71 (87) 0.20 (24) 0.09 (11) 0.0002
Control 0.57 (141) 0.40 (98) 0.04 (9)
Anti-CCP positive Case 0.69 (159) 0.28 (63) 0.03 (7) 0.0398
Control 0.59 (167) 0.38 (107) 0.04 (11)
Anti-CCP negative Case 0.70 (97) 0.22 (31) 0.08 (11) 0.0032
Control 0.59 (167) 0.38 (107) 0.04 (11)
CCP, cyclic citrullinated peptide; RF, rheumatoid factor. Values indicate the genotype frequencies and number (in brackets).
Table 4
Logistic regression analysis of rs729749 in cases stratified for autoantibody status
Status Subgroup Genotype CT versus CC Genotype TT versus CC
OR 95% CI P OR 95% CI P
All All 0.80 0.66 to 0.97 0.02 1.04 0.67 to 1.62 0.86
Women 0.94 0.75 to 1.17 0.56 1.01 0.60 to 1.71 0.97
Men 0.50 0.35 to 0.73 0.0002 1.20 0.52 to 2.81 0.67
RF positive All 0.85 0.69 to 1.04 0.12 0.92 0.56 to 1.53 0.76
Women 0.96 0.75 to 1.23 0.74 1.03 0.58 to 1.84 0.92
Men 0.59 0.39 to 0.88 0.009 0.74 0.26 to 2.12 0.58
RF negative All 0.70 0.54 to 0.90 0.006 1.24 0.71 to 2.14 0.45
Women 0.88 0.65 to 1.18 0.39 0.94 0.47 to 1.90 0.87
Men 0.34 0.20 to 0.60 0.0001 2.03 0.88 to 5.29 0.15
Anti-CCP positive All 0.86 0.70 to 1.07 0.17 1.01 0.61 to 1.71 0.98
Women 1.02 0.80 to 1.31 0.88 1.12 0.63 to 2.00 0.70
Men 0.54 0.36 to 0.83 0.003 0.79 0.28 to 2.24 0.65
Anti-CCP negative All 0.69 0.54 to 0.89 0.004 1.07 0.62 to 1.84 0.82
Women 0.82 0.61 to 1.10 0.19 0.86 0.43 to 1.73 0.67
Men 0.4 0.2 to 0.7 0.0004 1.8 0.7 to 4.6 0.26
CCP, cyclic citrullinated peptide; CI, confidence interval; OR, odds ratio; RF, rheumatoid factor.Arthritis Research & Therapy    Vol 9 No 5    Olsson et al.
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important the impact of the rs729749 SNP is for the identified
associated haplotype, we conducted a conditional analysis in
which the association of the haplotype was estimated while
controlling for the haplotype background of rs760519 and
rs2284027. This test gave an empirical P value of 0.01, which
is lower than for the associated haplotype, indicating that the
rs729749 SNP itself or a SNP in strong linkage disequilibrium
is causing the haplotype association.
Homozygosity could explain the genetic risk associated 
with rs729749
The rs726749 SNP is noncoding and located in the beginning
of intron 4 in NCF4. Analysis of the region using the UCSC
genome browser (March 2006 assembly) [38] revealed that it
is not located at any known transcription factor binding site or
regulatory element; however, there is a conserved regulatory
region (as predicted by the ESPERR regulatory potential
option) approximately 300 base pairs downstream of
rs729749. Nonetheless, the genetic effect of this SNP is not
obvious.
By looking at the genotype frequencies in RF-negative males
for rs729749, it appears as though both homozygous geno-
types are more common in the RA patients (Table 3). This led
us to perform an analysis to determine which genetic model
best fits the data. Not surprisingly, the homozygous model
(CC + TT versus CT) gave the best fit in the subgroup of RF-
negative men (OR = 2.67, 95% CI = 1.60 to 4.46; P  =
0.0002; Table 6). However, because the allele frequency of
the T-allele is quite low and few individuals are homozygous for
this allele, there is a degree of uncertainty in this prediction.
The CC genotype is clearly more common in the patients and
homozygosity at this locus also gives a significant genetic
model (Table 6).
Discussion
Here we report an association of the SNP rs729749, located
in the gene NCF4, with RA in Swedish RF/anti-CCP antibody
negative male patients. NCF4 is part of the NOX complex, and
our results support recent findings that ROS play a role in the
development of RA. However, because this is the first report
of an association between a gene in the NOX complex and
RA, genetic replication as well as functional studies will be
required before it is possible to determine conclusively
whether NCF4 is an RA susceptibility gene. Furthermore, the
results from this study do not exclude the possibility that the
other genes in the NOX complex could affect RA susceptibil-
ity. There could, for example, be epistatic effects between the
different genes in the complex.
There is a lack of consensus in the field about statistical signif-
icance levels in association studies. In this study we initially
used an α level of 0.05 to reduce the risk for overlooking
associations that are specific for a subgroup of RA patients.
There are strong medical and biological arguments in favour of
subgrouping RA patients, and an analysis of nonstratified sam-
ples might conceal a true association. In the initial analysis of
the genotype frequencies we found indications of association
with three SNPs, and stratification of the samples indicates
that the association for rs729749 is male specific and pre-
dominates in RF-negative disease. We also found a weaker
association in anti-CCP antibody negative disease, but at this
stage it is not possible to say whether this is due to the fact
that the presence of RFs and anti-CCP antibodies is depend-
ent [41] or whether the anti-CCP antibodies independently
influence genetic risk.
The detected association of rs729749 is strongest in RF-neg-
ative males, and therefore it is possible that this particular SNP
modulates the affected disease pathway so that it mainly influ-
ences the clinical disease in RF-negative RA, specifically in
men. However, it is not impossible that this pathway play a role
also in other subtypes of RA. The results from this study
strengthen the view that different combinations of genes are
involved in the disease progression in different RA subclasses
defined, for instance, by sex or autoantibody status. The most
striking aspect of the identified association of the rs729749
SNP is the clear sex specificity, indicating that the disease
pathway affected by the rs729749 SNP is specific to men.
The fact that RA is three times more common in women than
in men suggests that men and women respond differently to
factors that trigger the onset of RA and that some disease
pathways could be sex specific. The RF-negative specificity of
the association is not as striking as the sex specificity, but it
might still point toward which RA subgroup is affected by the
rs729749 SNP. Because both RFs and anti-CCP antibodies
can be detected before the appearance of any disease
symptoms [7,42], they might reflect or be part of initial disease
mechanisms that are only present in anti-CCP antibody or RF
positive patients. Furthermore, it has repeatedly been shown
that patients who are negative for these autoantibodies have a
less severe disease outcome than do anti-CCP antibody or RF
positive RA patients [10-12]. This further supports the view
that autoantibody negative RA is another variant of RA. Also,
Table 5
Haplotype analysis
Haplotypea Frequency Subgroup Empirical 
Pb
Cases Controls
TC 0.82 0.80 - 0.038
CT 0.15 0.16
TT 0.04 0.05
TC 0.81 0.77 men 0.029
CT 0.15 0.17
TT 0.03 0.06
aHaplotype of rs760519 and rs729749. bBased on 5,000 
permutations.Available online http://arthritis-research.com/content/9/5/R98
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the few genes confirmed to be associated with RA have been
shown mainly to affect subclasses of RA.
The well established association of the HLA-DRB1 alleles,
which encode the so-called shared epitope (SE), was recently
suggested to be restricted to anti-CCP antibody but not RF
positive RA [15,16,41]. However, it has also been shown that
SE alleles are associated with higher titres of autoantibodies
against type II collagen [43]. Interestingly, the HLA-DR3 locus,
which does not encode the SE, appears to be associated only
Figure 1
Haplotype blocks in NCF4 Haplotype blocks in NCF4. Three haplotype blocks were identified in NCF4. Block 2 contains the associated single nucleotide polymorphism (SNP) 
rs729749. Colour scheme of the linakge disequilibrium LD map is based on the standard D'/LOD option in the Haploview software. The LD blocks 
are calculated based on the CI method.Arthritis Research & Therapy    Vol 9 No 5    Olsson et al.
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with anti-CCP negative RA [41,44]. The recently discovered
PTPN22 risk allele has been shown to be associated with
both RF and anti-CCP antibody positive RA [43,45,46], but
there are conflicting data regarding the autoantibody restric-
tion of this association [47]. Furthermore, the reported associ-
ation of the PD-1.2A allele of the PDCD1 gene is restricted to
RF negative as well as SE negative RA [48]. Hence, even
though little is known about the precise disease mechanisms
in RA, it is obvious that the symptoms can be caused by sev-
eral different distinct disease pathways.
Because of the lack of certain autoantibodies, it is tempting to
speculate that RF or anti-CCP antibody negative RA patients
have a lesser B-cell component, and reports indicating that B-
cell depleting therapy is a less effective treatment for RF-neg-
ative RA supports such a view [49,50]. Several recent clinical
studies, however, have yielded conflicting results on B-cell
depletion efficiency [51], and more extensive studies are
required before any conclusions can be drawn about the B-
cell dependence in RF and anti-CCP antibody negative RA. In
addition, it is fair to assume that the autoantibody negative
forms of RA, in themselves, represent a heterogeneous collec-
tion of pathways related, for example, to osteoarthritis,
arthropathies, or lupus.
The rodent arthritis models are heterogeneous as well but they
may relate to more defined arthritis conditions than the human
disease. Interestingly, the pristane-induced arthritis model
used to identify the polymorphism in Ncf1 in rats is B-cell inde-
pendent. Studies have shown that transfer of T-cells from
genetically susceptible and immunized rats into genetically
resistant and un-immunized rats is enough to induce arthritis in
the resistant rat [52].
Both the HLA-DRB1 locus and PTPN22 are believed to affect
T-cell activation. HLA-DRB1 is expressed by antigen-present-
ing cells and restricts the presentation of antigens to T cells.
PTPN22 on the other hand has an intracellular effect, and the
amino acid shift to the disease-associated tryptophan impairs
the function of the Lyp protein, encoded by PTPN22, render-
ing it a less potent negative regulator of T-cell activation [53].
Studies in animal models as well as recent findings suggest
that the NOX complex could also be involved in T-cell activa-
tion [29,54]. ROS production has been found in antigen-pre-
senting cells, and it has also been shown that T-cell receptor
signalling is affected by oxidation of the T-cell membrane as
well as by intracellular levels of ROS [55,56]. Interestingly,
hydrogen peroxide generated from •O2
- produced by the NOX
complex can readily cross the cell membrane and inactivate
protein tyrosine phosphatases, including that encoded by
PTPN22, through oxidation of a specific cysteine residue [54].
ROS production of antigen-presenting cells, such as dendritic
cells, has been found to be crucial for the activation of T-cells
[28] and could therefore determine the immune response to
an antigen. Furthermore, recent work from our group highlights
the importance of the redox balance on the surface of T cells
for activation. T-cells originating from the Ncf1 mutated rat DA
have an increased number of reduced thiol groups on the cell
surface, which increases proliferation and activation [29]. Gel-
derman and coworkers [29] showed that T-cells originating
from the nonmutated E3 rats could be made arthritogenic by
increasing the number of reduced thiol groups on the cell sur-
face. Because NOX production could not be detected in T-
cells, it was concluded that the redox balance of T-cell sur-
faces is determined by other cells, such as macrophages or
dendritic cells.
In the rat a clear difference in the capacity to produce oxidative
burst is the result of a single SNP in Ncf1, resulting in the shift
from threonine to the disease-promoting methionine at posi-
tion 153 in the p47phox protein [21]. The consequences of the
amino acid shift have not yet been identified, although position
153 does not coincide with any critical binding sites. It is most
likely that the shift affects the three-dimensional structure of
the protein, impairing the binding capabilities to the other pro-
teins in the complex. The activation of the NOX complex is ini-
tiated through phosphorylation of the three cytoplasmic
proteins p47phox (NCF1), p67phox (NCF2) and p40phox (NCF4)
[23,26,57]. The phosphorylations lead to conformational
changes of p47phox, and subsequent translocation of the three
proteins to the membrane, where it interacts with and activates
the membrane bound complex flavocytochrome b558, which is
Table 6
Genetic models of rs729749 in RF negative males
Model Frequency of risk variant OR 95% CI P
Cases Controls
CC + TT versus CT 0.80 0.60 2.67 1.60 to 4.46 0.0002
CC versus CT 0.71 0.57 2.52 1.50 to 4.24 0.0004
TT versus CT 0.09 0.04 4.99 1.86 to 13.4 0.0016
CC versus CT + TT 0.71 0.57 1.89 1.18 to 3.01 0.0088
TT versus CC + CT 0.09 0.04 2.63 1.06 to 6.53 0.0476
CI, confidence interval; OR, odds ratio; RF, rheumatoid factor.Available online http://arthritis-research.com/content/9/5/R98
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composed of gp91phox (CYBB) and p22phox (CYBA) [24,58].
RAC2 also translocates to the membrane after dissociation
from Rho-guanine nucleotide dissociation inhibitor and inter-
acts with flavocytochrome b558 [23,59]. Studies show that
p67phox and Rac2 are critical for the function of the complex
[25,60], whereas p40phox and p47phox function as adaptor pro-
teins and are responsible for the assembly of the complex [61].
The precise role of p40phox is still debated, and there is evi-
dence of both positive and negative regulation of the NOX
complex [61-63]. Recent studies have suggested that p40phox,
as well as p47phox, functions by 'carrying' p67phox to the mem-
brane through the interaction with phospholipids [62,64].
Studies of mutations causing human chronic granulomatous
disease show that mutations in NCF1,  CYBB,  CYBA, or
NCF2 lead to a complete lack of function of the NOX complex
[65,66]. However, SNPs in less critical regions, like the 153
SNP in Ncf1 found in rat, apparently reduce but do not com-
pletely abolish ROS production, which leads to an increased
susceptibility to arthritis [21]. These facts indicate that the
SNPs of interest for examination in an RA association study of
the NOX complex will probably be located at noncritical
positions and will not completely abolish but only slightly mod-
ify binding to the other proteins.
The rs729749 SNP is located in the middle part of intron 4 in
NCF4. By studying the genome maps using the UCSC
genome browser, we could not find any evidence of it affecting
a transcription factor binding site or a known regulatory ele-
ment. However, there is a conserved regulatory region pre-
dicted approximately 300 base pairs downstream of
rs729749. The haplotype analysis indicates that rs729749, or
a SNP in very high LD, is responsible for the association
detected for the haplotype. Also, because the predicted regu-
latory region is very close to rs729749, it could very well con-
tain the causative SNP.
The genetic analysis of the association shows that the
homozygous model gives the best significance, indicating that
this could be the genetic effect. However, the low number of
samples in the subgroup of RF-negative males together with
the low frequency of the T allele make this assumption some-
what uncertain. Furthermore, it is not obvious what the func-
tional consequences of a homozygous effect would be. We
therefore chose to present all models tested in order to pro-
vide the full picture.
In the logistic regression analysis, weak associations were
also detected for RF and anti-CCP antibody positive disease.
One possible explanation for these findings is that some
patients could have been 'misdiagnosed' regarding autoanti-
body status. The diagnosis is made by measuring the autoan-
tibody titres, and certain threshold are used to determine
positive versus negative status. However, sometimes autoanti-
body status changes as the disease progresses, and therefore
there is a degree of uncertainty regarding autoantibody status.
A method or a strategy to apply multiple testing corrections
accurately in a case-control candidate gene association study
has not yet been established [67,68]. The conventional multi-
ple correction methods, such as Bonferroni, are considered by
some to be too stringent for large-scale studies [69,70]. The
Bonferroni correction method is used to correct for the
number of independent tests performed. However, in an asso-
ciation analysis neither the SNPs tested nor the different strat-
ified analyses are truly independent. The allele frequencies of
the SNPs are affected by the LD of the region, and the strati-
fied analyses are based on the same SNPs and samples as the
initial analysis and can therefore not be considered to be inde-
pendent from each other. Nonetheless, in order to obtain an
indication of the validity of the P values obtained in these anal-
yses, we used the Bonferroni correction method to estimate
an α level correcting for the number of tests (159) performed
in the frequency analysis. The 159 tests reflect the sex-strati-
fied analysis of all 51 SNPs (153) plus the stratified analysis of
RF and anti-CCP antibody status performed for rs729749,
rs789181 and rs1476002 in the male subset (6). Correcting
for 159 tests gives a new α level of 0.0003, which means that
only the association of rs729749 in RF-negative males passed
the significance threshold using this stringent method.
The EIRA study included mainly individuals born in Sweden.
Taking those born outside Sweden into consideration also,
97% were of Caucasian origin. In order to minimize potential
bias resulting from population stratification, we performed
logistic regression analyses in which ORs were adjusted for
age and residential area.
Conclusion
We found evidence of an RA-associated SNP in the NCF4
gene of the NOX complex. The association is specific for male
patients, with the strongest association found in RF-negative
RA. This finding supports the notion of RA being a heteroge-
neous disease caused by a variety of disease pathways that
are regulated by a variety of contributing risk genes. The
detected association with a component of the NOX complex
also strengthens previous evidence obtained in animal models
that suggests that the NOX complex and ROS have a major
impact on inflammation and autoimmunity. It is hoped that this
finding will help to elucidate the complex genetics that underlie
RA and autoimmunity.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
LMO has been the responsible investigator for the project and
has carried out SNP selection, genotype preparation, statisti-
cal analyses and drafted the manuscript. A-KL participated in
the design of the study and the statistical analyses. HK and LA
performed the logistic regression analysis. LP and LK were
responsible for the distribution of the EIRA cohort. HB hasArthritis Research & Therapy    Vol 9 No 5    Olsson et al.
Page 10 of 11
(page number not for citation purposes)
contributed with intellectual property to the study. RH con-




This work was supported by the Swedish Research Council, the Strate-
gic Science foundation, the Foundations of Craaford, Kock, Österlunds 
and the European Union Grants Autocure (LSHB-2006-018661) and 
Neuropromise (LSHM-LT-018637).
References
1. Seldin MF, Amos CI, Ward R, Gregersen PK: The genetics revo-
lution and the assault on rheumatoid arthritis.  Arthritis Rheum
1999, 42:1071-1079.
2. Gregersen PK, Silver J, Winchester RJ: The shared epitope
hypothesis. An approach to understanding the molecular
genetics of susceptibility to rheumatoid arthritis.  Arthritis
Rheum 1987, 30:1205-1213.
3. Weyand CM, Goronzy JJ: Association of MHC and rheumatoid
arthritis. HLA polymorphisms in phenotypic variants of rheu-
matoid arthritis.  Arthritis Res 2000, 2:212-216.
4. Begovich AB, Carlton VE, Honigberg LA, Schrodi SJ, Chokkalin-
gam AP, Alexander HC, Ardlie KG, Huang Q, Smith AM, Spoerke
JM, et al.: A missense single-nucleotide polymorphism in a
gene encoding a protein tyrosine phosphatase (PTPN22) is
associated with rheumatoid arthritis.  Am J Hum Genet 2004,
75:330-337.
5. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper
NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al.: The Amer-
ican Rheumatism Association 1987 revised criteria for the
classification of rheumatoid arthritis.  Arthritis Rheum 1988,
31:315-324.
6. Schellekens GA, Visser H, de Jong BA, van den Hoogen FH,
Hazes JM, Breedveld FC, van Venrooij WJ: The diagnostic prop-
erties of rheumatoid arthritis antibodies recognizing a cyclic
citrullinated peptide.  Arthritis Rheum 2000, 43:155-163.
7. Rantapaa-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell
G, Stenlund H, Sundin U, van Venrooij WJ: Antibodies against
cyclic citrullinated peptide and IgA rheumatoid factor predict
the development of rheumatoid arthritis.  Arthritis Rheum 2003,
48:2741-2749.
8. van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, de Jong BA,
Breedveld FC, Verweij CL, Toes RE, Huizinga TW: Autoantibod-
ies to cyclic citrullinated peptides predict progression to rheu-
matoid arthritis in patients with undifferentiated arthritis: a
prospective cohort study.  Arthritis Rheum 2004, 50:709-715.
9. Dorner T, Egerer K, Feist E, Burmester GR: Rheumatoid factor
revisited.  Curr Opin Rheumatol 2004, 16:246-253.
10. Turesson C, Jacobsson LT, Sturfelt G, Matteson EL, Mathsson L,
Ronnelid J: Rheumatoid factor and antibodies to cyclic citrulli-
nated peptides are associated with severe extra-articular
manifestations in rheumatoid arthritis.  Ann Rheum Dis 2007,
66:59-64.
11. Mewar D, Coote A, Moore DJ, Marinou I, Keyworth J, Dickson MC,
Montgomery DS, Binks MH, Wilson AG: Independent associa-
tions of anti-cyclic citrullinated peptide antibodies and rheu-
matoid factor with radiographic severity of rheumatoid
arthritis.  Arthritis Res Ther 2006, 8:R128.
12. van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Toes RE,
Huizinga TW: Antibodies to citrullinated proteins and differ-
ences in clinical progression of rheumatoid arthritis.  Arthritis
Res Ther 2005, 7:R949-R958.
1 3 . M e y e r  O ,  L a b a r r e  C ,  D o u g a d o s  M ,  G o u p i l l e  P ,  C a n t a g r e l  A ,
Dubois A, Nicaise-Roland P, Sibilia J, Combe B: Anticitrullinated
protein/peptide antibody assays in early rheumatoid arthritis
for predicting five year radiographic damage.  Ann Rheum Dis
2003, 62:120-126.
14. Vencovsky J, Machacek S, Sedova L, Kafkova J, Gatterova J, Pesa-
kova V, Ruzickova S: Autoantibodies can be prognostic markers
of an erosive disease in early rheumatoid arthritis.  Ann Rheum
Dis 2003, 62:427-430.
15. van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Huizinga
TW, Toes RE, de Vries RR: The HLA-DRB1 shared epitope alle-
les are primarily a risk factor for anti-cyclic citrullinated pep-
tide antibodies and are not an independent risk factor for
development of rheumatoid arthritis.  Arthritis Rheum 2006,
54:1117-1121.
16. Klareskog L, Stolt P, Lundberg K, Kallberg H, Bengtsson C, Grune-
wald J, Ronnelid J, Harris HE, Ulfgren AK, Rantapaa-Dahlqvist S, et
al.: A new model for an etiology of rheumatoid arthritis: smok-
ing may trigger HLA-DR (shared epitope)-restricted immune
reactions to autoantigens modified by citrullination.  Arthritis
Rheum 2006, 54:38-46.
17. van der Helm-van Mil AH, Verpoort KN, le Cessie S, Huizinga TW,
de Vries RR, Toes RE: The HLA-DRB1 shared epitope alleles
differ in the interaction with smoking and predisposition to
antibodies to cyclic citrullinated peptide.  Arthritis Rheum 2007,
56:425-432.
18. Hirschhorn JN, Daly MJ: Genome-wide association studies for
common diseases and complex traits.  Nat Rev Genet 2005,
6:95-108.
19. Freimer N, Sabatti C: The use of pedigree, sib-pair and associ-
ation studies of common diseases for genetic mapping and
epidemiology.  Nat Genet 2004, 36:1045-1051.
20. Olofsson P, Holmberg J, Pettersson U, Holmdahl R: Identification
and isolation of dominant susceptibility loci for pristane-
induced arthritis.  J Immunol 2003, 171:407-416.
21. Olofsson P, Holmberg J, Tordsson J, Lu S, Akerstrom B, Holmdahl
R: Positional identification of Ncf1 as a gene that regulates
arthritis severity in rats.  Nat Genet 2003, 33:25-32.
22. Hultqvist M, Olofsson P, Holmberg J, Backstrom BT, Tordsson J,
Holmdahl R: Enhanced autoimmunity, arthritis, and encephalo-
myelitis in mice with a reduced oxidative burst due to a muta-
tion in the Ncf1 gene.  Proc Natl Acad Sci USA 2004,
101:12646-12651.
23. Nauseef WM: Assembly of the phagocyte NADPH oxidase.
Histochem Cell Biol 2004, 122:277-291.
24. Groemping Y, Rittinger K: Activation and assembly of the
NADPH oxidase: a structural perspective.  Biochem J 2005,
386:401-416.
25. Bokoch GM, Diebold BA: Current molecular models for NADPH
oxidase regulation by Rac GTPase.  Blood 2002,
100:2692-2696.
26. Sheppard FR, Kelher MR, Moore EE, McLaughlin NJ, Banerjee A,
Silliman CC: Structural organization of the neutrophil NADPH
oxidase: phosphorylation and translocation during priming
and activation.  J Leukoc Biol 2005, 78:1025-1042.
27. Vignais PV: The superoxide-generating NADPH oxidase: struc-
tural aspects and activation mechanism.  Cell Mol Life Sci
2002, 59:1428-1459.
28. Matsue H, Edelbaum D, Shalhevet D, Mizumoto N, Yang C, Mum-
mert ME, Oeda J, Masayasu H, Takashima A: Generation and
function of reactive oxygen species in dendritic cells during
antigen presentation.  J Immunol 2003, 171:3010-3018.
29. Gelderman KA, Hultqvist M, Holmberg J, Olofsson P, Holmdahl R:
T cell surface redox levels determine T cell reactivity and
arthritis susceptibility.  Proc Natl Acad Sci USA 2006,
103:12831-12836.
30. Antonell A, de Luis O, Domingo-Roura X, Perez-Jurado LA: Evolu-
tionary mechanisms shaping the genomic structure of the Wil-
liams-Beuren syndrome chromosomal region at human
7q11.23.  Genome Res 2005, 15:1179-1188.
The following Additional files are available online:
Additional file 1
An Word file containing a table that shows a table of all 
SNPs evaluated for association with RA in this study.
See http://www.biomedcentral.com/content/
supplementary/ar2299-S1.docAvailable online http://arthritis-research.com/content/9/5/R98
Page 11 of 11
(page number not for citation purposes)
31. Heyworth PG, Noack D, Cross AR: Identification of a novel NCF-
1 (p47-phox) pseudogene not containing the signature GT
deletion: significance for A47 degrees chronic granulomatous
disease carrier detection.  Blood 2002, 100:1845-1851.
32. The HapMap Genome browser   [http://www.hapmap.org]
33. dbSNP (NCBI)   [http://www.ncbi.nlm.nih.gov/SNP]
34. Barrett JC, Fry B, Maller J, Daly MJ: Haploview: analysis and vis-
ualization of LD and haplotype maps.  Bioinformatics 2005,
21:263-265.
35. Simple Interactive Statistical Analysis   [http://www.quantita
tiveskills.com/sisa/calculations/bonfer.htm]
36. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumen-
stiel B, Higgins J, DeFelice M, Lochner A, Faggart M, et al.: The
structure of haplotype blocks in the human genome.  Science
2002, 296:2225-2229.
37. Purcell S, Daly MJ, Sham PC: WHAP: haplotype-based associa-
tion analysis.  Bioinformatics 2007, 23:255-256.
38. The UCSC Genome browser   [http://genome.ucsc.edu]
39. Padyukov L, Silva C, Stolt P, Alfredsson L, Klareskog L: A gene-
environment interaction between smoking and shared epitope
genes in HLA-DR provides a high risk of seropositive rheuma-
toid arthritis.  Arthritis Rheum 2004, 50:3085-3092.
40. Stolt P, Bengtsson C, Nordmark B, Lindblad S, Lundberg I,
Klareskog L, Alfredsson L: Quantification of the influence of
cigarette smoking on rheumatoid arthritis: results from a pop-
ulation based case-control study, using incident cases.  Ann
Rheum Dis 2003, 62:835-841.
41. Irigoyen P, Lee AT, Wener MH, Li W, Kern M, Batliwalla F, Lum RF,
Massarotti E, Weisman M, Bombardier C, et al.: Regulation of
anti-cyclic citrullinated peptide antibodies in rheumatoid
arthritis: contrasting effects of HLA-DR3 and the shared
epitope alleles.  Arthritis Rheum 2005, 52:3813-3818.
42. Aho K, Palosuo T, Raunio V, Puska P, Aromaa A, Salonen JT: When
does rheumatoid disease start?  Arthritis Rheum 1985,
28:485-489.
43. Burkhardt H, Huffmeier U, Spriewald B, Bohm B, Rau R, Kallert S,
Engstrom A, Holmdahl R, Reis A: Association between protein
tyrosine phosphatase 22 variant R620W in conjunction with
the HLA-DRB1 shared epitope and humoral autoimmunity to
an immunodominant epitope of cartilage-specific type II colla-
gen in early rheumatoid arthritis.  Arthritis Rheum 2006,
54:82-89.
44. Verpoort KN, van Gaalen FA, van der Helm-van Mil AH, Schreuder
GM, Breedveld FC, Huizinga TW, de Vries RR, Toes RE: Associ-
ation of HLA-DR3 with anti-cyclic citrullinated peptide anti-
body-negative rheumatoid arthritis.  Arthritis Rheum 2005,
52:3058-3062.
45. Lee AT, Li W, Liew A, Bombardier C, Weisman M, Massarotti EM,
Kent J, Wolfe F, Begovich AB, Gregersen PK: The PTPN22
R620W polymorphism associates with RF positive rheumatoid
arthritis in a dose-dependent manner but not with HLA-SE
status.  Genes Immun 2005, 6:129-133.
46. Michou L, Lasbleiz S, Rat AC, Migliorini P, Balsa A, Westhovens R,
Barrera P, Alves H, Pierlot C, Glikmans E, et al.: Linkage proof for
PTPN22, a rheumatoid arthritis susceptibility gene and a
human autoimmunity gene.  Proc Natl Acad Sci USA 2007,
104:1649-1654.
47. Pierer M, Kaltenhauser S, Arnold S, Wahle M, Baerwald C,
Hantzschel H, Wagner U: Association of PTPN22 1858 single-
nucleotide polymorphism with rheumatoid arthritis in a Ger-
man cohort: higher frequency of the risk allele in male com-
pared to female patients.  Arthritis Res Ther 2006, 8:R75.
48. Prokunina L, Castillejo-Lopez C, Öberg F, Gunnarsson I, Berg L,
Magnusson V, Brookes AJ, Tentler D, Kristjansdottir H, Grondal G,
et al.: A regulatory polymorphism in PDCD1 is associated with
susceptibility to systemic lupus erythematosus in humans.
Nat Genet 2002, 32:666-669.
49. De Vita S, Zaja F, Sacco S, De Candia A, Fanin R, Ferraccioli G:
Efficacy of selective B cell blockade in the treatment of rheu-
matoid arthritis: evidence for a pathogenetic role of B cells.
Arthritis Rheum 2002, 46:2029-2033.
50. Leandro MJ, Edwards JC, Cambridge G: Clinical outcome in 22
patients with rheumatoid arthritis treated with B lymphocyte
depletion.  Ann Rheum Dis 2002, 61:883-888.
51. Edwards JC, Cambridge G: B-cell targeting in rheumatoid
arthritis and other autoimmune diseases.  Nat Rev Immunol
2006, 6:394-403.
52. Holmberg J, Tuncel J, Yamada H, Lu S, Olofsson P, Holmdahl R:
Pristane, a non-antigenic adjuvant, induces MHC class II-
restricted, arthritogenic T cells in the rat.  J Immunol 2006,
176:1172-1179.
53. Bottini N, Musumeci L, Alonso A, Rahmouni S, Nika K, Rostam-
khani M, MacMurray J, Meloni GF, Lucarelli P, Pellecchia M, et al.:
A functional variant of lymphoid tyrosine phosphatase is asso-
ciated with type I diabetes.  Nat Genet 2004, 36:337-338.
54. Reth M: Hydrogen peroxide as second messenger in lym-
phocyte activation.  Nat Immunol 2002, 3:1129-1134.
55. Sahaf B, Heydari K, Herzenberg LA, Herzenberg LA: Lymphocyte
surface thiol levels.  Proc Natl Acad Sci USA 2003,
100:4001-4005.
56. Gringhuis SI, Papendrecht-van der Voort EA, Leow A, Nivine
Levarht EW, Breedveld FC, Verweij CL: Effect of redox balance
alterations on cellular localization of LAT and downstream T-
cell receptor signaling pathways.  Mol Cell Biol 2002,
22:400-411.
57. Lapouge K, Smith SJ, Groemping Y, Rittinger K: Architecture of
the p40-p47-p67phox complex in the resting state of the
NADPH oxidase. A central role for p67phox.  J Biol Chem 2002,
277:10121-10128.
58. Groemping Y, Lapouge K, Smerdon SJ, Rittinger K: Molecular
basis of phosphorylation-induced activation of the NADPH
oxidase.  Cell 2003, 113:343-355.
59. Heyworth PG, Bohl BP, Bokoch GM, Curnutte JT: Rac translo-
cates independently of the neutrophil NADPH oxidase compo-
nents p47phox and p67phox. Evidence for its interaction with
flavocytochrome b558.  J Biol Chem 1994, 269:30749-30752.
60. Nisimoto Y, Ogawa H, Miyano K, Tamura M: Activation of the fla-
voprotein domain of gp91phox upon interaction with N-termi-
nal p67phox (1–210) and the Rac complex.  Biochemistry 2004,
43:9567-9575.
61. Kuribayashi F, Nunoi H, Wakamatsu K, Tsunawaki S, Sato K, Ito T,
Sumimoto H: The adaptor protein p40(phox) as a positive reg-
ulator of the superoxide-producing phagocyte oxidase.  Embo
J 2002, 21:6312-6320.
62. Ellson C, Davidson K, Anderson K, Stephens LR, Hawkins PT:
PtdIns3P binding to the PX domain of p40phox is a physiolog-
ical signal in NADPH oxidase activation.  Embo J 2006,
25:4468-4478.
63. Lopes LR, Dagher MC, Gutierrez A, Young B, Bouin AP, Fuchs A,
Babior BM: Phosphorylated p40PHOX as a negative regulator
of NADPH oxidase.  Biochemistry 2004, 43:3723-3730.
64. Ueyama T, Tatsuno T, Kawasaki T, Tsujibe S, Shirai Y, Sumimoto
H, Leto TL, Saito N: A regulated adaptor function of p40phox:
distinct p67phox membrane targeting by p40phox and by
p47phox.  Mol Biol Cell 2007, 18:441-454.
65. Cross AR, Noack D, Rae J, Curnutte JT, Heyworth PG: Hemato-
logically important mutations: the autosomal recessive forms
of chronic granulomatous disease (first update).  Blood Cells
Mol Dis 2000, 26:561-565.
66. Heyworth PG, Curnutte JT, Rae J, Noack D, Roos D, van Koppen
E, Cross AR: Hematologically important mutations: X-linked
chronic granulomatous disease (second update).  Blood Cells
Mol Dis 2001, 27:16-26.
67. Zondervan KT, Cardon LR: The complex interplay among fac-
tors that influence allelic association.  Nat Rev Genet 2004,
5:89-100.
68. Gregersen PK: Pathways to gene identification in rheumatoid
arthritis: PTPN22 and beyond.  Immunol Rev 2005, 204:74-86.
69. Nyholt DR: A simple correction for multiple testing for single-
nucleotide polymorphisms in linkage disequilibrium with each
other.  Am J Hum Genet 2004, 74:765-769.
70. Cardon LR, Bell JI: Association study designs for complex
diseases.  Nat Rev Genet 2001, 2:91-99.